(Q46851166)

English

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/25800393

1 reference

Europe PubMed Central

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/25800393

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Ashish M Kamat

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Thomas W Flaig

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

H Barton Grossman

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Badrinath Konety

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Donald Lamm

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Edward Uchio

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jason A Efstathiou

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

John A Taylor

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

0 references

publication date

24 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/25800393

Nature Reviews Urology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

225-235

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

24 March 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1038/nrurol.2015.58

0 references

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Statins and the effect of BCG on bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Effect of statin use on outcomes of non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Definition and management of patients with bladder cancer who fail BCG therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Treatment options for BCG failures.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

An international telecytologic quiz on urinary cytology reveals educational deficits and absence of a commonly used classification system.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Recognition and treatment of BCG failure in bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Indication and timing of cystectomy in high-risk bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Superficial bladder cancer: the role of interferon-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 t

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Bladder cancer: long-term follow-up results of patients treated with radical radiation

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Smac mimetics as new cancer therapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Functionalized gold nanorods for thermal ablation treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

21 January 2018

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Use of statins and outcome of BCG treatment for bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter Study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of mainte

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Defining bacillus Calmette-Guerin refractory superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Urinary IL‐2 assay for monitoring intravesical bacillus Calmette‐Guérin response of superficial bladder cancer during induction course and maintenance therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Adjuvant Chemotherapy of Recurrent Superficial Transitional Cell Carcinoma: Results of a European Organization for Research on Treatment of Cancer Randomized Trial Comparing Intravesical Instillation of Thiotepa, Doxorubicin and Cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Treatment of superficial (T1) tumours of the bladder by radical radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Enhanced antitumor effect of Bacillus Calmette-Guérin in combination with fibrinogen on urinary bladder tumor.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2015.58

31 March 2020

Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The optimal management of T1 high-grade bladder cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival of patients with carcinoma in situ of the urinary bladder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25800393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRUROL.2015.58

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800393%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46851166&oldid=2134714777"